Related Experiment Video

Updated: Apr 22, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Association between rs1049673 polymorphism in CD36 and premature coronary heart disease

J J Che1, Y X Shao2, G P Li2

  • 1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China jingjinche@126.com.

Genetics and Molecular Research : GMR
|October 10, 2014
PubMed

Insights

This study links specific CD36 gene variations (rs1049673, rs7755, rs321159) to premature coronary heart disease in Chinese Han patients. These genetic factors, combined with traditional risks, increase susceptibility to early heart disease.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Epidemiology
  • Internal Medicine

Background:

  • Premature coronary heart disease (PCHD) poses a significant health challenge, particularly in China.
  • Identifying genetic predispositions alongside traditional risk factors is crucial for understanding PCHD etiology.
  • The CD36 gene is implicated in lipid metabolism and inflammation, key processes in atherosclerosis.

Purpose of the Study:

  • To investigate the association between CD36 gene polymorphisms (rs1049673, rs7755, rs321159) and PCHD in a Chinese Han population.
  • To identify traditional risk factors for PCHD in this cohort.
  • To explore the combined effect of genetic variations and clinical factors on PCHD risk.

Main Methods:

  • Case-control study recruiting 79 PCHD patients and 56 controls.
  • Coronary arteriography and laboratory blood tests to assess cardiovascular status and risk factors.
  • Genotyping of CD36 polymorphisms at rs1049673, rs7755, and rs321159 using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or similar methods.
  • Unconditional logistic regression analysis to determine risk factors.

Main Results:

  • PCHD patients exhibited higher rates of male gender, smoking, diabetes, and metabolic syndrome.
  • Elevated levels of triglycerides (TG), LDL-cholesterol (LDL-C), oxidized LDL (ox-LDL), white blood cell count (WBC), uric acid (UA), and fasting blood glucose (FBG) were observed in the PCHD group.
  • Lower levels of HDL-cholesterol (HDL-C) were found in PCHD patients.
  • Specific genotypes (GA for rs1049673, AA for rs7755, TT for rs321159) were associated with family history of PCHD and high LDL-C.
  • Logistic regression identified male gender, diabetes, high TG, high LDL-C, and C carriers of rs1049673 as significant risk factors for PCHD.

Conclusions:

  • CD36 gene polymorphisms, particularly at rs1049673, rs7755, and rs321159, are associated with PCHD in Chinese Han individuals.
  • Genetic predisposition, especially with high LDL-C and specific CD36 genotypes, contributes to PCHD risk.
  • Traditional risk factors including male gender, diabetes, dyslipidemia (high TG, high LDL-C), and metabolic syndrome remain critical determinants of PCHD.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

7.7K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
887